Graham Parry, an analyst from Bank of America Securities, maintained the Sell rating on GlaxoSmithKline (GSK – Research Report). The associated ...
Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £16.90.
British drugmaker GSK said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the ...
Massachusetts families are still struggling to find alternatives almost a year after GlaxoSmithKline canceled a widely ...
WJET Erie on MSN2mon
Drugmaker to settle nearly 80,000 Zantac lawsuits for up to $2.2 billionUK-based pharmaceutical giant GSK, or GlaxoSmithKline, has announced that it has agreed to settle nearly 80,000 state-level ...
With vaccine hesitancy leading to a rise in measles cases, the FDA's approval of GlaxoSmithKline's venerable vaccine Priorix for sale in the US looks timely. Priorix was first launched in Europe ...
At GlaxoSmithKline, we never lose sight of the fact that patients are at the core of what we do and that millions of lives are impacted by cancer. The patient’s voice is at the heart of our ...
Nomura cuts GSK Consumer to 'reduce' on high valuations Nomura Financial Advisory and Securities India has downgraded GlaxoSmithKline Consumer Healthcare to "reduce" from "buy" citing high ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback